Patents by Inventor Justin D. Dietrich

Justin D. Dietrich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrrolidine Main Protease Inhibitors as Antiviral Agents
    Publication number: 20240158368
    Abstract: Pyrrolidine main protease inhibitors are described that are effective as antiviral compounds.
    Type: Application
    Filed: October 12, 2023
    Publication date: May 16, 2024
    Applicant: AbbVie Inc.
    Inventors: David A. Degoey, Michael R. Schrimpf, David J. Hardee, Jacob Ludwig, Eric R. Miller, Timothy R. Hodges, Alberto Munoz, Sarah J. Perlmutter, Huan-Qiu X. Li, Alvin Jang, Elizabeth L. Noey, Gregory A. Gfesser, Edgars Jecs, Robert G. Schmidt, Justin D. Dietrich, Xenia B. Searle, Boguslaw P. Nocek, Andrew Bogdan
  • Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose
    Patent number: 11312668
    Abstract: The present invention relates to a method of carrying out an organic reaction in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose.
    Type: Grant
    Filed: October 1, 2020
    Date of Patent: April 26, 2022
    Assignees: ABBVIE INC., ABBVIE DEUTSCHLAND GMBH & CO. KG
    Inventors: Wilfried Braje, Katarina Britze, Justin D. Dietrich, Anais Jolit, Johannes Kaschel, Johanna Klee, Tanja Lindner
  • TETRACYCLIC BROMODOMAIN INHIBITORS
    Publication number: 20210070756
    Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R6, Y1, Y2, Y3, A1, A2, A3, and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
    Type: Application
    Filed: November 16, 2020
    Publication date: March 11, 2021
    Inventors: Steven D. Fidanze, Dachun Liu, Robert A. Mantei, Keith F. McDaniel, John Pratt, George S. Sheppard, Le Wang, Andrew Bogdan, James H. Holms, Justin D. Dietrich, Jasmina Marjanovic, Lisa A. Hasvold, Yujia Dai
  • ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE
    Publication number: 20210017100
    Abstract: The present invention relates to a method of carrying out an organic reaction in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose.
    Type: Application
    Filed: October 1, 2020
    Publication date: January 21, 2021
    Inventors: Wilfried BRAJE, Katarina BRITZE, Justin D. DIETRICH, Anais JOLIT, Johannes KASCHEL, Johanna KLEE, Tanja LINDNER
  • Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose
    Patent number: 10836688
    Abstract: The present invention relates to a method of carrying out an organic reaction in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose.
    Type: Grant
    Filed: January 14, 2020
    Date of Patent: November 17, 2020
    Assignees: ABBVIE INC., ABBVIE DEUTSCHLAND GMBH & CO. KG
    Inventors: Wilfried Braje, Katarina Britze, Justin D. Dietrich, Anais Jolit, Johannes Kaschel, Johanna Klee, Tanja Lindner
  • TETRACYCLIC BROMODOMAIN INHIBITORS
    Publication number: 20200291027
    Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R6, Y1, Y2, Y3, A1, A2, A3, and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
    Type: Application
    Filed: March 23, 2020
    Publication date: September 17, 2020
    Inventors: Steven D. Fidanze, Dachun Liu, Robert A. Mantei, Keith F. McDaniel, John Pratt, George S. Sheppard, Le Wang, Andrew Bogdan, James H. Holms, Justin D. Dietrich, Jasmina Marjanovic, Lisa A. Hasvold, Yujia Dai
  • ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE
    Publication number: 20200148610
    Abstract: The present invention relates to a method of carrying out an organic reaction in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose.
    Type: Application
    Filed: January 14, 2020
    Publication date: May 14, 2020
    Inventors: Wilfried BRAJE, Katarina BRITZE, Justin D. DIETRICH, Anais JOLIT, Johannes KASCHEL, Johanna KLEE, Tanja LINDNER
  • TETRACYCLIC BROMODOMAIN INHIBITORS
    Publication number: 20190389861
    Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R6, Y1, Y2, Y3, A1, A2, A3, and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
    Type: Application
    Filed: January 22, 2019
    Publication date: December 26, 2019
    Inventors: Steven D. Fidanze, Dachun Liu, Robert A. Mantei, Keith F. McDaniel, John Pratt, George S. Sheppard, Le Wang, Andrew Bogdan, James H. Holms, Justin D. Dietrich, Jasmina Marjanovic, Lisa A. Hasvold, Yujia Dai
  • Tricyclic modulators of TNF signaling
    Patent number: 10266532
    Abstract: The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: April 23, 2019
    Assignee: AbbVie Inc.
    Inventors: Eric C. Breinlinger, Phil B. Cox, Justin D. Dietrich, Kristine E. Frank, Michael M. Friedman, Huan-Qui Li, Kenton L. Longenecker, Augustine T. Osuma, Ann Marie Rowley, Anil Vasudevan, Noel S. Wilson, Jerome Daanen, Stevan Djuric, Amanda W. Dombrowski, Arthur Gomtsyan, Robert Schmidt
  • Indazolones as modulators of tnf signaling
    Patent number: 10160748
    Abstract: The disclosure provides indazolone compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the disclosure may be useful for treating immunological and oncological conditions.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: December 25, 2018
    Assignee: AbbVie Inc.
    Inventors: Maria Argiriadi, Eric Breinlinger, Justin D. Dietrich, Michael Friedman, David Ihle, Michael Morytko, Kelly Mullen, Augustine Osuma, Gloria Y. LoSchiavo, Noel S. Wilson
  • TETRACYCLIC BROMODOMAIN INHIBITORS
    Publication number: 20180298003
    Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R6, Y1, Y2, Y3, A1, A2, A3, and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
    Type: Application
    Filed: June 26, 2018
    Publication date: October 18, 2018
    Inventors: Steven D. Fidanze, Dachun Liu, Robert A. Mantei, Keith F. McDaniel, John Pratt, George S. Sheppard, Le Wang, Andrew Bogdan, James H. Holms, Justin D. Dietrich, Jasmina Marjanovic, Lisa A. Hasvold, Yujia Dai
  • INDAZOLONES AS MODULATORS OF TNF SIGNALING
    Publication number: 20180215764
    Abstract: The disclosure provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the disclosure are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: December 22, 2017
    Publication date: August 2, 2018
    Inventors: Eric C. Breinlinger, Andrew Burchat, Justin D. Dietrich, Michael Friedman, David Ihle, David Kinsman, Kelly Mullen, Augustine T. Osuma, Anil Vasudevan, Noel S. Wilson
  • Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors
    Patent number: 10035800
    Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R6, Y1, Y3, A1, A2, A3 and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: July 31, 2018
    Assignee: AbbVie Inc.
    Inventors: Steven D. Fidanze, Dauchun Liu, Robert A. Mantei, Keith F. McDaniel, John Pratt, George S. Sheppard, Le Wang, Andrew Bogdan, James H. Holms, Justin D. Dietrich, Jasmina Marjanovic, Lisa A. Hasvold, Yujia Dai
  • TRICYCLIC MODULATORS OF TNF SIGNALING
    Publication number: 20180179198
    Abstract: The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.
    Type: Application
    Filed: December 1, 2017
    Publication date: June 28, 2018
    Inventors: Eric C. Breinlinger, Phil B. Cox, Justin D. Dietrich, Kristine E. Frank, Michael M. Friedman, Huan-Qui Li, Kenton L. Longenecker, Augustine T. Osuma, Ann Marie Rowley, Anil Vasudevan, Noel S. Wilson
  • Indane inhibitors of EED and methods of their use
    Patent number: 9957274
    Abstract: Compounds having a structure of Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein A1, A2, A3, A4, A5, n, and m are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various EED-related conditions or diseases, including cancer, by administration of such compounds are also provided.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: May 1, 2018
    Assignee: AbbVie Inc.
    Inventors: Michael R. Michaelides, Michael L. Curtin, Huan-Qiu Li, Marina A Pliushchev, Ying Wang, Hongyu H. Zhao, Richard F. Clark, Alan S. Florjancic, Zhiqin Ji, Mariazel Torrent, Ramzi F. Sweis, Anil Vasudevan, Justin D. Dietrich
  • INDAZOLONES AS MODULATORS OF TNF SIGNALING
    Publication number: 20180086737
    Abstract: The disclosure provides indazolone compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the disclosure may be useful for treating immunological and oncological conditions.
    Type: Application
    Filed: August 7, 2017
    Publication date: March 29, 2018
    Inventors: Maria Argiriadi, Eric Breinlinger, Justin D. Dietrich, Michael Friedman, David Ihle, Michael Morytko, Kelly Mullen, Augustine Osuma, Gloria Y. LoSchiavo, Noel S. Wilson
  • INDANE INHIBITORS OF EED AND METHODS OF THEIR USE
    Publication number: 20170320880
    Abstract: Compounds having a structure of Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein A1, A2, A3, A4, A5, n, and m are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various EED-related conditions or diseases, including cancer, by administration of such compounds are also provided.
    Type: Application
    Filed: May 5, 2017
    Publication date: November 9, 2017
    Inventors: Michael R. Michaelides, Michael L. Curtin, Huan-Qiu Li, Marina A. Pliushchev, Ying Wang, Hongyu H. Zhao, Richard F. Clark, Alan S. Florjancic, Zhiqin Ji, Mariazel Torrent, Ramzi F. Sweis, Anil Vasudevan, Justin D. Dietrich
  • ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE
    Publication number: 20170217850
    Abstract: The present invention relates to a method of carrying out an organic reaction in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose.
    Type: Application
    Filed: January 27, 2017
    Publication date: August 3, 2017
    Inventors: Wilfried BRAJE, Katarina BRITZE, Justin D. DIETRICH, Anais JOLIT, Johannes KASCHEL, Johanna KLEE, Tanja LINDNER
  • INDAZOLONES AS MODULATORS OF TNF SIGNALING
    Publication number: 20160304496
    Abstract: The disclosure provides indazolone compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the disclosure may be useful for treating immunological and oncological conditions.
    Type: Application
    Filed: April 15, 2016
    Publication date: October 20, 2016
    Inventors: Maria Argiriadi, Eric Breinlinger, Justin D. Dietrich, Michael Friedman, David Ihle, Michael Morytko, Kelly Mullen, Augustine Osuma, Glora Y. Lo Schiavo, Noel S. Wilson
  • TETRACYCLIC BROMODOMAIN INHIBITORS
    Publication number: 20160039821
    Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R6, Y1, Y2, Y3, A1, A2, A3 and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
    Type: Application
    Filed: March 12, 2014
    Publication date: February 11, 2016
    Inventors: Steven D. Fidanze, Dachun Liu, Robert A. Mantei, Keith F. McDaniel, John Pratt, George S. Sheppard, Le Wang, Andrew Bogdan, James H. Holms, Justin D. Dietrich, Jasmina Marjanovic, Lisa A. Hasvold, Yujia Dai